Nivolumab

​Nivolumab is FDA approved for the treatment of classical Hodgkin lymphoma (cHL) in:

• Adult and pediatric (12 years and older) patients with previously untreated Stage III or IV classical Hodgkin lymphoma in combination with doxorubicin, vinblastine, and dacarbazine (AVD).
• Adult patients with classical Hodgkin lymphoma that has relapsed or progressed after:
  • Autologous hematopoietic stem cell transplantation (HSCT) and brentuximab vedotin, or 
  • 3 or more lines of systemic therapy that includes autologous HSCT.